MicroRNAs in the Management of Heart Failure

Title:MicroRNAs in the Management of Heart Failure

Volume: 28 Issue: 24

Author(s): Aimilios Kalampogias*, Gerasimos Siasos*, Evangelos Oikonomou, Konstantinos Mourouzis, Evanthia Bletsa, Panagiota K. Stampouloglou, Efstratios Katsianos, Konstantinos Vlasis, Georgios Marinos, Georgios Charalambous, Manolis Vavouranakis and Dimitris Tousoulis

Affiliation:

• 1st Cardiology Clinic, Hippokration Hospital, National and Kapodistrian University of Athens Medical School, Athens,Greece

• 1st Cardiology Clinic, Hippokration Hospital, National and Kapodistrian University of Athens Medical School, Athens,Greece

Keywords: Cardiac fibrosis, cardiomyocytes, cardiac remodeling, inflammation, cell therapy, regeneration.

Abstract:

Background: In recent years much research has been devoted to the deployment of biomarkers in the field of heart failure.

Objectives: To study the potential of post-transcriptional regulation by microRNAs on the diagnosis, management and therapy of heart failure.

Methods: Literature search focuses on the role of microRNAs in heart failure.

Results: MicroRNAs are expressed and regulated in the course of the pathological manifestations of heart failure (HF). This wide and uncharted area of genetic imprints consisting of small non-coding RNA molecule is upregulated and released into the bloodstream from organs under certain conditions and or stress. The use of genetically based strategies for the management of HF has gained great interest in the field of biomedical science because they can be used as biomarkers providing information regarding cardiac status and function. They also appear as promising tools with therapeutic potential because of their ability to induce changes at the cellular level without creating alterations in the gene sequence. In addition, with the advances in genomic sequencing, quantification and synthesis in technologies of microRNAs identification as well as the growing knowledge of the biology of miRNAs and their involvement in HF, it is expected to favorably affect the prognosis of HF patients.

Conclusion: MicroRNAs are involved in the regulation of multibiological processes involved in the progress of heart failure. More studies are needed to achieve a clinical valuable implementation of microRNAs in the management of HF.

Cite this article as:

Kalampogias Aimilios *, Siasos Gerasimos *, Oikonomou Evangelos , Mourouzis Konstantinos , Bletsa Evanthia , Stampouloglou K. Panagiota , Katsianos Efstratios , Vlasis Konstantinos , Marinos Georgios , Charalambous Georgios , Vavouranakis Manolis and Tousoulis Dimitris , MicroRNAs in the Management of Heart Failure, Current Medicinal Chemistry 2021; 28(24) . https://dx.doi.org/10.2174/0929867328666210218181441